SCHEMBL14830681

SCHEMBL14830681

OCC(c1ccc(Cl)cc1)c1cccc(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CNR1 P21554 1/20 0.41
CACNA1G O43497 1/20 0.40
CACNA2D1 P54289 1/20 0.40
CACNA1B Q00975 1/20 0.40
CACNB1 Q02641 1/20 0.40
CACNA1C Q13936 1/20 0.40
LMNA P02545 2/20 0.40
IDO1 P14902 2/20 0.40
TDO2 P48775 2/20 0.40
CASR P41180 1/20 0.40
P2RX7 Q99572 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
OPRL1 P41146 1/20 0.40
ALDH1A1 P00352 1/20 0.40
ALPL P05186 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6450353 0.92 ACP3 (0.53) ACP3MEN1KMT2ACACNA1GCACNA2D1
SCHEMBL10775144 0.92 ACP3 (0.52) ACP3MEN1KMT2ACACNA1GCACNA2D1
SCHEMBL4058257 0.88 IDO1 (0.50) MEN1KMT2ACNR1CACNA1GCACNA2D1
SCHEMBL1979065 0.85 TSHR (0.44) MEN1KMT2ACNR1LMNAIDO1
SCHEMBL11552637 0.79 HTR2A (0.44) ACP3LMNA
SCHEMBL17398566 0.78 ACP3 (0.41) ACP3MEN1KMT2ALMNAIDO1
SCHEMBL5556253 0.76 LMNA (0.42) ACP3CACNA1GLMNAP2RX7ADRB2
SCHEMBL5555304 0.76 AOC3 (0.60) SLC6A2SLC6A4
SCHEMBL6002784 0.76 ACP3 (0.44) ACP3MEN1KMT2ALMNAIDO1
SCHEMBL8324166 0.74 ACP3 (0.47) ACP3MEN1KMT2ACACNA1GCACNA2D1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2760845-A1 HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER Amgen Inc. (US) 2014-08-06 EP disclosed
WO-2013049250-A1 HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2013-04-04 WO disclosed